PhysioTelemeter for Autonomic Monitoring

描述(申请人提供)：提出了一种“PhysioTelemeter(Tm)”系统，用于对脊髓损伤(SCI)和糖尿病的自主神经系统功能进行生理研究和临床监测。该系统将允许在需要长期使用或自由移动的多个位置对多个生理变量进行非侵入性、非侵入性、无线监测。 第一阶段系统将由3个电池供电的PhysioTelemeter(Tm)组成，每个都在一个独特的无线电频率上传输到一个远程接收器和一台计算机以供显示和存档。 每个遥测仪将从4个示例性传感器(生物电、温度、振动和电池电压)传输数据，距离长达10米。一期遥测仪的直径和重量约为美国25美分硬币的直径和重量，但厚度是美国的两倍，将使用锂币电池电池工作8小时以上。这种小尺寸和轻重量将允许在活动受试者中使用PhysioTelemeter(Tm)暂时附着在感兴趣区域的皮肤上进行测量。 第一阶段的临床合作者包括一名在脊髓损伤病理生理学方面具有专业知识的物理医学和康复临床医生，以及一名在糖尿病患者自主神经障碍方面具有临床专业知识的生理学家。这些合作者将在不同阶段对该技术进行审查和评论，以指导该技术，并将在为第二阶段做准备的健康受试者上进行有限的人体测试来评估该系统， 在第二阶段，临床合作者将广泛利用第一阶段原型系统，以确定该方法在他们的临床实践和研究中的实用价值。将添加两个主动测量(皮肤灌注和阻抗)。该系统将进一步优化，包括使用定制集成电路来减小体积和功率，将射程增加到30M，增加5个频道，总共8个，开发耐环境的封装，并提供可充电电池系统。

DESCRIPTION (provided by applicant): A "PhysioTelemeter(tm)" system for physiological research and clinical monitoring of autonomic nervous system function in Spinal Cord Injury (SCI) and Diabetes is proposed. The system will allow non-invasive, unobtrusive, wireless monitoring of multiple physiological variables at multiple locations where long term use or freedom of movement is desirable. The Phase-1 system will consist of 3 battery powered PhysioTelemeters(tm), each transmitting on a unique radio frequency to a remote receiver and a computer for display and archive. Each telemeter will transmit data from 4 exemplary sensors (bioelectric, temperature, vibration and battery voltage) up to 10M in distance. The Phase-1 telemeters will be approximately the diameter and weight of a US quarter, but twice as thick, and will operate for over 8 hours from a lithium coin cell battery. This small size and light weight will allow measurements in active subjects with the PhysioTelemeters(tm) temporarily adhered to the skin over the regions of interest. Clinical collaborators for Phase-1 include a Physical Medicine and Rehabilitation clinician with expertise in SCI pathophysiology, and a physiologist with clinical expertise in dysautonomia in patients with diabetes. These collaborators will review and critique the technology at various stages to guide the technology, and will evaluate the system with limited human testing on healthy subjects in preparation for Phase-2, During Phase-2, clinical collaborators will utilize the Phase-1 prototype system extensively to determine the practical utility of the approach in their clinical practice and research. Two active measurements (skin perfusion and impedance) will be added. The system will be further optimized including use of custom integrated circuits to decrease size and power, increasing the range to 30M, adding 5 more frequency channels for a total of 8, developing an environmentally resistant package, and providing a rechargeable battery system.